Henry Schein (NASDAQ:HSIC) Director Purchases $691,900.00 in Stock

Henry Schein, Inc. (NASDAQ:HSIC) Director William Daniel purchased 10,000 shares of the stock in a transaction that occurred on Monday, May 11th. The stock was bought at an average price of $69.19 per share, with a total value of $691,900.00. Following the completion of the acquisition, the director owned 20,000 shares in the company, valued at $1,383,800. This represents a 100.00% increase in their position. The transaction was disclosed in a document filed with the SEC, which is available through this link.

Henry Schein Price Performance

Shares of NASDAQ HSIC opened at $72.61 on Friday. Henry Schein, Inc. has a 1-year low of $61.94 and a 1-year high of $89.29. The business has a 50-day moving average of $74.94 and a 200-day moving average of $75.28. The company has a debt-to-equity ratio of 0.59, a current ratio of 1.36 and a quick ratio of 0.75. The company has a market capitalization of $8.27 billion, a price-to-earnings ratio of 21.94, a PEG ratio of 1.74 and a beta of 0.82.

Henry Schein (NASDAQ:HSIC) last announced its earnings results on Tuesday, May 5th. The company reported $1.32 EPS for the quarter, beating the consensus estimate of $1.20 by $0.12. The business had revenue of $3.37 billion for the quarter, compared to the consensus estimate of $3.34 billion. Henry Schein had a return on equity of 15.44% and a net margin of 2.95%.The company’s revenue was up 6.3% on a year-over-year basis. During the same period last year, the business posted $1.15 EPS. Henry Schein has set its FY 2026 guidance at 5.230-5.370 EPS. On average, equities analysts anticipate that Henry Schein, Inc. will post 5.31 EPS for the current fiscal year.

Hedge Funds Weigh In On Henry Schein

Hedge funds have recently added to or reduced their stakes in the business. CYBER HORNET ETFs LLC bought a new position in shares of Henry Schein in the 2nd quarter worth about $25,000. MUFG Securities EMEA plc bought a new stake in shares of Henry Schein during the 2nd quarter valued at about $27,000. Flagship Harbor Advisors LLC acquired a new stake in Henry Schein during the fourth quarter worth about $30,000. Federated Hermes Inc. acquired a new stake in Henry Schein during the fourth quarter worth about $32,000. Finally, Los Angeles Capital Management LLC bought a new position in Henry Schein in the fourth quarter worth about $37,000. Institutional investors and hedge funds own 96.62% of the company’s stock.

Wall Street Analyst Weigh In

Several equities research analysts recently issued reports on HSIC shares. BTIG Research began coverage on shares of Henry Schein in a research note on Thursday, April 16th. They set a “neutral” rating on the stock. Barrington Research set a $97.00 target price on Henry Schein and gave the company an “outperform” rating in a research note on Wednesday, February 25th. Robert W. Baird set a $97.00 target price on Henry Schein in a research report on Wednesday, May 6th. Leerink Partners reissued a “market perform” rating on shares of Henry Schein in a report on Monday, March 9th. Finally, UBS Group restated a “neutral” rating and set a $85.00 price objective (down from $87.00) on shares of Henry Schein in a research note on Wednesday, May 6th. Six research analysts have rated the stock with a Buy rating, seven have issued a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the stock currently has a consensus rating of “Hold” and an average price target of $86.83.

Henry Schein Company Profile

Henry Schein, Inc is a leading global distributor of healthcare products and services, primarily serving office-based dental, medical and animal health practitioners. The company operates through three principal segments—Schein Dental, Schein Medical and Animal Health—each offering a comprehensive portfolio of consumable products, equipment, instruments and related value-added services. With a focus on improving practice efficiency and patient care, Henry Schein provides everything from dental restorative materials and orthodontic appliances to vaccines, pharmaceuticals and diagnostic devices for physicians, as well as pet health products and veterinary equipment for animal health professionals.

In addition to its broad product offering, Henry Schein delivers a suite of technology and service solutions aimed at streamlining workflows and enhancing clinical outcomes.